Tofacitinib and baricitinib are the pan-JAK inhibitors (JAK1/JAK3) approved for the treatment of moderate to severe rheumatoid arthritis but they showed dose-related toxicities [4]. Here, JAK1 is linked to rheumatoid arthritis.